Clinical trials: Acute Ischemia
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Acute Coronary Syndrome
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE-2 (NCT05918861)
- Testing
- Dalcetrapib
- Where
- 231 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- DalCor Pharmaceuticals
Ischemic Stroke, Acute
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus…
- Trial name
- FRIDA-CT (NCT07324837)
- Testing
- non-immunogenic staphylokinase
- Where
- 17 sites in Russia
- Volunteers
- 990 people
- Sponsor
- Supergene, LLC
Acute Coronary Syndrome
PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers
This clinical study will adopt an open-label, randomized, multiple-dose, two-crossover design to explore the pharmacokinetic and pharmacodynamic profiles of Vicagrel Capsules and Clopidogrel Tablets in Healthy Subjects with…
- Trial name
- NCT05162053
- Testing
- vicagrel Capsules, Clopidogrel Tablets
- Where
- 3 sites in United States, China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Ischemic Stroke
ReStore Thrombectomy Trial for Flow Restoration in Acute Ischemic Stroke Patients
The ReStore™ Thrombectomy device restores blood flow in the neurovascular by removing thrombus in patients experiencing ischemic stroke.
- Trial name
- NCT01437774
- Testing
- thrombectomy (ReStore or Merci)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Reverse Medical Corporation
Stroke, Acute
THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA
The purpose of this study is to test the experimental drug "THR-18" given together with the drug "tissue plasminogen activator" for the treatment of stroke. Tissue plasminogen activator is also called "tPA".
- Trial name
- NCT01957774
- Testing
- THR-18
- Where
- Ukraine
- Volunteers
- 30 people
- Sponsor
- D-Pharm Ltd.
Acute Ischemic Stroke AIS
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
- Trial name
- STEVIA (NCT06995625)
- Testing
- SNE-101
- Where
- 3 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- S&Ebio Co. Ltd.
Acute Ischemic Stroke
A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
The study is a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic…
- Trial name
- RESET (NCT05188417)
- Testing
- Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution
- Where
- China
- Volunteers
- 266 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III All-comers Orsiro Safety and Performance Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-III (NCT01553526)
- Where
- 43 sites in Austria, Chile and 11 more
- Volunteers
- 1,356 people
- Sponsor
- Biotronik AG
Infarction, Myocardial
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Multinational, multicentre, randomised, prospective, open, parallel group study directly comparing two glycoprotein-IIb/IIIa inhibitors, abciximab and eptifibatide, added early to standard treatment before primary PCI of STEMI…
- Trial name
- NCT00426751
- Testing
- Abciximab, Eptifibatide
- Where
- 24 sites in France, Germany
- Volunteers
- 429 people
- Sponsor
- GlaxoSmithKline
Acute Lower Limb Arterial Occlusion
The ArtixASCEND Study
This study is a post-market, prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions.
- Trial name
- NCT07135895
- Testing
- Artix Thrombectomy System
- Where
- 23 sites in United States
- Volunteers
- 250 people
- Sponsor
- Inari Medical
Anemia, Sickle Cell, Sickle Cell Anemia
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
Sickle Cell disease is caused by an inherited hemoglobin disorder. Healthy red blood cells are discoid and can deform and move through small blood vessels to carry oxygen to all parts of the body.
- Conditions
- Anemia, Sickle Cell, Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders
- Trial name
- NCT01925001
- Testing
- MP4CO, Sodium chloride solution
- Where
- 14 sites in Bahrain, Belgium and 7 more
- Sponsor
- Sangart
Cerebrovascular Accident
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
This study will investigate the effects of a potential neuroprotectant compound, YM872, in the treatment of acute ischemic stroke.
- Trial name
- NCT00044070
- Testing
- YM872 (zonampanel)
- Where
- 89 sites in United States, Austria and 4 more
- Sponsor
- Astellas Pharma Inc
Coronary Disease
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual…
- Trial name
- NCT00621855
- Testing
- dabigatran etexilate
- Where
- 167 sites in United States, Belgium and 22 more
- Volunteers
- 1,878 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Acute Stroke
APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke
This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up study to collect comprehensive information on technical and clinical success and safety of the use of APERIO® Hybrid(17/21)…
- Trial name
- NCT04457479
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- Acandis GmbH
Acute Coronary Syndrome
An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)
The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India.
- Trial name
- TREASURE (NCT02408224)
- Where
- 31 sites in India
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome
This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar…
- Trial name
- ALPACS (NCT00728988)
- Testing
- Atorvastatin
- Where
- 26 sites in China, South Korea
- Volunteers
- 499 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: an acute stroke due to a blood clot that formed outside the…
- Conditions
- Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
- Trial name
- OCEANIC-STROKE (NCT05686070)
- Testing
- Asundexian (BAY2433334)
- Where
- 741 sites in United States, Argentina and 35 more
- Volunteers
- 12,327 people
- Sponsor
- Bayer